StockNews.com initiated coverage on shares of Amarin (NASDAQ:AMRN - Free Report) in a research report report published on Tuesday. The firm issued a sell rating on the biopharmaceutical company's stock.
Amarin Price Performance
Shares of AMRN stock traded up $0.27 during trading hours on Tuesday, hitting $9.30. The stock had a trading volume of 296,245 shares, compared to its average volume of 70,551. The stock has a market capitalization of $3.82 billion, a price-to-earnings ratio of -103.33 and a beta of 1.38. Amarin has a one year low of $7.08 and a one year high of $20.80. The stock's 50-day moving average price is $9.93 and its two-hundred day moving average price is $10.53.
Amarin (NASDAQ:AMRN - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by ($1.20). The firm had revenue of $62.31 million during the quarter, compared to the consensus estimate of $32.37 million. Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. As a group, equities research analysts predict that Amarin will post -0.15 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Amarin
A number of institutional investors and hedge funds have recently modified their holdings of the stock. New York State Common Retirement Fund bought a new stake in shares of Amarin in the 4th quarter worth about $68,000. Waterfront Wealth Inc. lifted its stake in Amarin by 181.4% in the fourth quarter. Waterfront Wealth Inc. now owns 2,481,766 shares of the biopharmaceutical company's stock worth $1,204,000 after purchasing an additional 1,599,956 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Amarin by 8.8% during the third quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company's stock valued at $816,000 after buying an additional 104,939 shares during the period. Arkfeld Wealth Strategies L.L.C. grew its stake in shares of Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 20,000 shares during the last quarter. Finally, LCM Capital Management Inc grew its stake in shares of Amarin by 3.1% during the fourth quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company's stock valued at $407,000 after buying an additional 25,100 shares during the last quarter. Hedge funds and other institutional investors own 22.25% of the company's stock.
Amarin Company Profile
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
See Also
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
